Status:
COMPLETED
Solid Tumors Using Ixabepilone and Dasatinib
Lead Sponsor:
Medstar Health Research Institute
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Patients are being asked to take part in this study because they have been diagnosed with an advanced solid tumor that is not responding to standard treatments. This study will find the highest dose o...
Eligibility Criteria
Inclusion
- Have a solid tumor malignancy that is metastatic or locally advanced/unresectable
- Progression through standard therapy
- Histological documentation of cancer
- Must be off prior chemotherapy or radiation therapy for at least 3 weeks
- Must have adequate organ and marrow function prior to the start of study treatment as defined by the protocol
- Must be able to swallow oral medication (dasatinib must be swallowed whole)
- Must be available for protocol-required follow-up
Exclusion
- Patients with a malignancy (other than the one treated in this study) which required radiotherapy or systemic therapy within the past 5 years
- Symptomatic brain metastasis that is either untreated or uncontrolled by surgery and or radiotherapy
- A known, prior, severe (NCI CTC Grade 3/Grade 4) history of hypersensitivity reaction to a drug formulated in Cremophor (polyoxyethylated castor oil)
- A serious, uncontrolled medical disorder or active infection including pericardial or pleural effusion of any grade,uncontrolled or significant cardiovascular disease,a bleeding disorder.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00717704
Start Date
July 1 2008
End Date
May 1 2011
Last Update
August 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington Cancer Institute
Washington D.C., District of Columbia, United States, 20010